Target regimen profiles for treatment of tuberculosis: A WHO document

European Respiratory Journal

Volumn 49, Issue 1, 2017, Pages

  Lienhardt, Christian ^a   Nahid, Payam ^b   Rich, Michael L ^c,d,e   Bansbach, Cathy ^f   Kendall, Emily A ^g   Churchyard, Gavin ^h,i   González Angulo, Lice ^a   D’Ambrosio, Lia ^a   Migliori, Giovanni Battista ^a   Raviglione, Mario ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e PARTNERS IN HEALTH   (United States)

^f BILL AND MELINDA GATES FOUNDATION   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h AURUM INSTITUTE   (South Africa)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT; ANTIRETROVIRUS AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; EDITORIAL; HUMAN; PRIORITY JOURNAL; SHELF LIFE; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION; COMMUNICABLE DISEASE CONTROL; DRUG INTERACTION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; INFECTIOUS DISEASE MEDICINE; LUNG TUBERCULOSIS; PULMONOLOGY; STANDARDS; THEORETICAL MODEL; TUBERCULOSIS;

ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; INFECTIOUS DISEASE MEDICINE; MODELS, THEORETICAL; PULMONARY MEDICINE; RIFAMPIN; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 85016089046     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02352-2016     Document Type: Editorial

References (39)

1. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1980; 1: 231–241.
2. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516–528.
3. Hughes J, Isaakidis P, Andries A, et al. Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients. Eur Respir J 2015; 46: 271–274.
4. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63: e147–e195.
5. Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394–402.
6. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205: Suppl. 2, S241–S249.
7. Zumla A, Chakaya J, Centis R, et al. Tuberculosis treatment and management – an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med 2015; 3: 220–234.
8. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151–2160.
9. Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564–574.
10. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance (WHO/HTM/TB/2013.6). Geneva, World Health Organization, 2013.
11. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance (WHO/HTM/TB2014.23). Geneva, World Health Organization, 2014.
12. RESIST-TB. DR-TB Clinical Trials Progress Report. www.resisttb.org/?page_id=1602
13. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014; 44: 1412–1417.
14. Nunn AJ, Rusen ID, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014; 15: 353.
15. Working Group for New TB Drugs. Clinical pipeline. www.newtbdrugs.org/pipeline/clinical Date last accessed: September 19, 2016.
16. Gospodarevskaya E, Tulloch O, Bunga C, et al. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens. Int J Tuberc Lung Dis 2014; 18: 810–817.
17. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554–565.
18. Winters N, Butler-Laporte G, Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur Respir J 2015; 46: 1461–1470.
19. Semvua HH, Kibiki GS, Kisanga ER, et al. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. Ther Drug Monit 2015; 37: 22–32.
20. Tiberi S, Payen MC, Sotgiu G, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J 2016; 47: 1235–1243.
21. Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59: 1049–1063.
22. Vasakova M. Challenges of antituberculosis treatment in patients with difficult clinical conditions. Clin Respir J 2015; 9: 143–152.
23. Koser CU, Javid B, Liddell K, et al. Drug-resistance mechanisms and tuberculosis drugs. Lancet 2015; 385: 305–307.
24. Gao J, Ma Y, Du J, et al. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis. BMC Pulm Med 2016; 16: 26.
25. Food and Drug Administration. Guidance for Industry and Review Staff: Target Product Profile – a Strategic Development Process Tool. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm080593.pdf
26. World Health Organization. Target Regimen Profiles for TB Treatment (WHO/HTM/TB/2016.16). Geneva, World Health Organization, 2016.
27. Uplekar M, Weil D, Lonnroth K, et al. WHO’s new End TB Strategy. Lancet 2015; 385: 1799–1801.
28. World Health Organization. Global tuberculosis report 2016 (WHO/HTM/TB/2016.13). Geneva, World Health Organization, 2016.
29. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2012; 42: 156–168.
30. World health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. (WHO/HTM/TB/2011.6). Geneva, World Health Organization, 2011.
31. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
32. Falzon D, Mirzayev F, Wares F, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J 2015; 45: 150–160.
33. WHO treatment guidelines for drug-resistant tuberculosis – 2016 update (WHO/HTM/TB/2016.04). Geneva, World Health Organization, 2016.
34. Van Deun A, Maug AKJ, Salim MAH, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684–692.
35. Kuaban C, Noeske J, Rieder H, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517–524.
36. Piubello A, Harouna SH, Souleymane M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188–1194.
37. Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015; 385: 1738–1747.
38. Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430–1442.
39. Brigden G, Nyang’wa B-T, du Cros P, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ 2014; 92: 68–74.